Salvage therapy for refractory or relapsed acute lymphocytic leukemia

Hematology/Oncology Clinics of North America

Volumn 15, Issue 1, 2001, Pages 163-205

  Garcia Manero, G ^a   Thomas, D A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACLACINOMYCIN; AMSACRINE; ANTHRACYCLINE DERIVATIVE; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BORTEZOMIB; BRYOSTATIN; CLOFARABINE; CYTARABINE; DOXORUBICIN; EPIPODOPHYLLOTOXIN; ETOPOSIDE; FLAVOPIRIDOL; FOLIC ACID ANTAGONIST; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; NELARABINE; NUCLEOSIDE ANALOG; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; STEROID; TENIPOSIDE; TEZACITABINE; TRIMETREXATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; ZORUBICIN;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; APOPTOSIS; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; HUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 0035093834     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70204-5     Document Type: Article

References (239)

1. Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: A Pediatric Oncology Group study
2. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group study
3. Proteasome inhibitors: A novel class of potent and effective antitumor agents
4. Report from the International Bone Marrow Transplant Registry
5. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory, or recurrent acute lymphoblastic leukemia
6. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
7. Sequential combination of high dose ara-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma
8. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL)
9. Idarubicin plus ARA-C followed by allogeneic or autologous bone marrow transplantation in advanced acute lymphoblastic leukemia
10. Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults
11. Improved outcome with T-cell-depleted bone marrow transplantation for acute leukemia
12. Adolescent and adult acute lymphoblastic leukemia: Prognostic features and outcome of therapy. A study of 293 patients
13. Role of BCL-2 and cell cycle regulatory proteins for corticosensitivity assessment in childhood acute lymphoblastic leukaemia
14. A phase II study of high-dose cytosine arabinoside in the treatment of acute leukaemia in adults
15. Marrow transplantation for acute lymphoblastic leukemia: Factors affecting relapse and survival
16. Bone marrow transplantation for acute lymphoblastic leukaemia
17. Intensive retreatment of adults and children with acute lymphoblastic leukemia
18. Strategies for the treatment of recurrent acute lymphoblastic leukemia in adults
19. Marrow transplantation from HLA-blastic unrelated donors for treatment of hematologic malignancies
20. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148)
21. Rubidazone in adults with previously treated acute leukemia and blast cell phase of chronic myelocytic leukemia: A Southwest Oncology Group study
22. Bone marrow transplantation may cure patients with acute leukemia never achieving remission with chemotherapy
23. Bone marrow transplantation for acute lymphoblastic leukemia
24. Second allogeneic bone marrow transplantation in acute leukemia: A multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)
25. Successful reinduction of patients with acute lymphoblastic leukemia who relapse following bone marrow transplantation
26. Allogeneic versus autologous marrow transplantation for patients with acute lymphoblastic leukemia in first or second marrow remission
27. Marrow transplantation for patients with acute lymphoblastic leukemia: The Seattle experience
28. Chemotherapy versus transplantation in acute leukaemia
29. Prolonged survival of B-lineage acute lymphoblastic leukemia cells is accompanied by overexpression of bcl-2 protein
30. Expression of bcl-2 proto-oncogene in adult acute lymphoblastic leukemia
31. Combination chemotherapy: Theory and practice
32. Autologous bone marrow transplantation in acute lymphoblastic leukemia: Biological and clinical aspects
33. Autologous bone marrow transplantation in acute lymphoblastic leukaemia
34. Mini-allografts: Ongoing trials in humans
35. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins
36. Allogeneic hematopoietic transplantation as adoptive immunotherapy: Induction of graft-versus-malignancy as primary therapy
37. Donor leukocyte infusion as salvage therapy in an adult with relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation
38. Adult acute lymphoblastic leukemia at relapse: Cytogenetic, immunophenotypic, and molecular changes
39. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
40. The biology and treatment of acute lymphoblastic leukemia in adults
41. Acute lymphoblastic leukemia: A comprehensive review with emphasis on biology and therapy
42. Phase I study of liposomal daunorubicin in patients with acute leukemia
43. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity
44. Phase I trial of trimetrexate (TMTX) in acute leukemias
45. Promising approaches in acute leukemia
46. Treatment of low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy
47. Feasibility and timing of unrelated donor identification for patients with ALL
48. FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission
49. Transient complete remission of acute lymphoblastic leukemia in relapse after allogeneic bone marrow transplantation induced by donor leukocyte transfusions
50. Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation: Multivariate analysis of factors affecting graft-versus-host disease, relapse, and relapse-free survival
51. Autologous bone marrow transplantation for acute lymphoblastic leukemia
52. Effects of a selective inhibitor of the ABL tyrosine kinase on the growth of BCR-ABL positive cells
53. Activity of an ABL specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemia, including chronic myelogenous leukemia in blast crisis
54. Effects of Campath-1H antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
55. Treatment of human B-cell precursor leukemia in SCID mice by using a combination of the anti-CD19 immunotoxin B43-PAP with the standard chemotherapeutic drugs vincristine, methylprednisolone, and L-asparaginase
56. Reinduction therapy for adult acute leukemia with Adriamycin, vincristine, and prednisone: A Southwest Oncology Group study
57. Moderate dose methotrexate, vincristine, asparaginase, and dexamethasone for treatment of adult acute lymphocytic leukemia
58. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia
59. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia
60. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia
61. Allogeneic bone marrow transplantation with T cell-depleted partially matched related donors for advanced acute lymphoblastic leukemia in children and adults: A comparative matched cohort study
62. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
63. Allogeneic bone marrow transplantation as therapy for primary induction failure for patients with acute leukemia
64. Relapse after allogeneic bone marrow transplantation for acute leukaemia: A survey by the EBMT of 117 cases
65. Treatment of relapsed or refractory adult acute lymphocytic leukemia
66. High expression of bcl-2 is the rule in acute lymphoblastic leukemia, except in Burkitt subtype at presentation, and is not correlated with prognosis
67. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity
68. Compound GW506U78 in refractory hematologic malignancies: Relationship between cellular pharmacokinetics and clinical response
69. Survival after relapse in childhood acute lymphoblastic leukemia: Impact of site and time to first relapse - The Children's Cancer Group Experience
70. A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: The Memorial Hospital experience since 1969
71. Idarubicin and high-dose cytarabine in the treatment of refractory, and relapsed acute lymphoblastic leukemia
72. Treatment of primary, refractory and relapsed acute lymphoblastic leukaemia in children and adults: The GIMEMA/AIEOP experience
73. Treatment of adults with acute lymphoblastic leukaemia in first bone marrow relapse: Results of the ALL R-87 protocol
74. Outcome of cord-blood transplantation from related and unrelated donors: Eurocord Transplant Group and the European Blood and Marrow Transplantation Group
75. Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT
76. Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: Prognostic implications
77. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion
78. Treatment of relapsed and refractory, acute leukaemia with high-dose cytosine arabinoside and etoposide
79. Mechanisms of methotrexate resistance in acute leukemia: Decreased transport and polyglutamylation
80. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: Clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement
81. Allogeneic bone marrow transplantation for leukaemia in Europe: Report from the Working Party on Leukaemia European Group for Bone Marrow Transplantation
82. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory, or relapsed acute leukaemia
83. Anti-B4-blocked ricin: A phase I trial of 7-day continuous infusion in patients with B-cell neoplasms
84. Transplantation of anergic histoincompatible bone marrow allografts
85. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency
86. BCL-2 expression in childhood leukemia versus spontaneous apoptosis, drug induced apoptosis, and in vitro drug resistance
87. Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation
88. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro
89. Chemotherapy versus allogeneic or autologous bone marrow transplantation in second complete remission of acute lymphoblastic leukemia
90. Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission
91. Treatment of refractory, acute lymphoblastic leukemia in adults with high dose cytosine arabinoside and mitoxantrone (HAM)
92. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults
93. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia
94. Treatment of acute lymphoblastic leukemia
95. Improved outcome in adult B-cell acute lymphoblastic leukemia
96. Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia
97. Nonhereditary p53 mutations in T-cell acute lymphoblastic leukemia are associated with the relapse phase
98. DNA methylation changes in hematologic malignancies: Biologic and clinical implications
99. Bryostatin 1, a unique biological response modifier: Antileukemic activity, in vitro
100. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia
101. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory, acute lymphocytic leukemia
102. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory, acute lymphocytic leukemia
103. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard and high-risk acute lymphocytic leukemia
104. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia
105. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia
106. L-Asparaginase and PEG asparaginase - Past, present, and future
107. Campath-1H Collaborative Study Group: Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine
108. High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study
109. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: Identification of host-derived antidonor allocytotoxic T lymphocytes
110. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program
111. Mitoxantrone and standard dose cytosine arabinoside therapy in refractory, or relapsed acute leukemia
112. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia
113. Second allogeneic bone marrow transplantation for post-transplant leukemia relapse: Results of a survey of 66 cases in 24 Japanese institutes
114. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory, hematologic malignancies
115. A pediatric phase I trial and pharmacokinetic study of thioguanine administered by continuous IV infusion
116. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia
117. A pilot study of dose-intensive anthracyclines for acute lymphoblastic leukemia (ALL) using liposomal daunorubicin (LD) with hyperfractionated cyclophosphamide (CTX), vincristine (VCR), and prednisone (PDN) (Hyper-CVXD)
118. Autologous transplantation of an immuno-magnetic bead purged marrow in patients with relapsed acute lymphoblastic leukemia
119. Phase I clinical and pharmacological study of clofarabine
120. The proto-oncogene Bcl-2 and its role in regulating apoptosis
121. 2-Amino-9-β-arabinosyl-6-methogy-9H-guanine (GW506U, Compound 506U) is highly active in patients with T-cell malignancies: Results of a phase I trial in pediatric and adult patients with refractory hematological malignancies
122. Autologous bone marrow transplantation in 2502 patients with acute leukemia in Europe: A retrospective study
123. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 8811
124. Enhanced MDR1 gene expression in human T-cell leukemia virus-1 infected patients offers new prospects for therapy
125. Evaluation of AMSA in previously treated patients with acute leukemia: Results of therapy in 109 adults
126. High-dose cytosine arabinoside and mitoxantrone in previously treated acute leukemia patients
127. Improved results of treatment of adult acute lymphoblastic leukemia
128. Relapse of leukemia and lymphoma after marrow transplant: A review of cases with extramedullary relapse
129. Mitoxantrone and continuous infusion of cytosine arabinoside in refractory and relapsed acute lymphoblastic leukemia
130. Multidrug resistance: Clinical relevance in acute leukemia
131. Autologous bone marrow transplantation with monoclonal antibody purged marrow for children with acute lymphoblastic leukemia in second remission-Spanish Working Party for BMT in Children
132. Preclinical and phase I and II trials of rituximab
133. Interleukin-4 induces programmed cell death (apoptosis) in cases of high-risk acute lymphoblastic leukemia
134. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia
135. T-cell depletion of HLA-identical transplants in leukemia
136. Therapy of relapsed acute lymphocytic leukemia: A 5-year experience with high dose Ara-C
137. Treatment of refractory and relapsed adult acute leukemia using a uniform chemotherapy protocol
138. Allogeneic or autologous stem cell transplantation following salvage chemotherapy for adults with refractory or relapsed acute lymphoblastic leukemia
139. Intensive salvage chemotherapy for primary refractory or first relapsed adult acute lymphoblastic leukemia: Results of a prospective trial
140. Treatment of adult patients with acute lymphocytic leukemia in relapse
141. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
142. Melphalan-total body irradiation and autologous bone marrow transplantation for adult acute leukemia beyond first remission
143. Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: Long-term follow-up
144. Results of two different conditioning regimens followed by ABMT in refractory acute lymphoblastic leukemia
145. Treatment of human B-cell precursor leukemia in SCID mice using a combination of the investigational biotherapeutic agent B43-PAP with cytosine arabinoside
146. Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarbine, mitoxantrone, and etoposide (PAME) chemotherapy
147. Treatment of relapsed adult acute lymphoblastic leukemia with fludarabine and cytosine arabinoside followed by granulocyte colony-stimulating factor (FLAG-GCSF)
148. Systemic high-dose ara-C for the treatment of meningeal leukemia in adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma
149. Relapse of acute leukemia after marrow transplantation - Natural history and results of subsequent therapy
150. Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980s: A report from the IBMTR
151. Second HLA-identical sibling transplants for leukemia recurrence
152. B4, a human B lymphocyte associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes
153. Compound 506 has activity in mature lymphoid leukemia
154. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia, European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia
155. A phase II study to determine the safety and anti-leukemic effects of ST1571 in adult patients with Philadelphia chromosome positive acute leukemias
156. Mitoxantrone in patients with acute leukemia in relapse
157. Mitoxantrone, vincristine, and prednisone in adults with relapsed or primarily refractory, acute lymphocytic leukemia and terminal deoxynucleotidyl transferase positive blastic phase chronic myelocytic leukemia
158. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia
159. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia
160. High-dose methotrexate for the remission induction of refractory adult acute lymphocytic leukemia
161. Idarubicin in acute leukemias: Experience of the Italian Cooperative Group GIMEMA
162. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL 101,731, a novel ribonucleoside diphosphate reductase inhibitor
163. 5-Aza-2′-deoxycytidine (Decitabine) and 5-azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends
164. Phase I study of continuous infusion 6-thioguanine in patients with acute leukemia
165. Relationship between leukemic cell retention of cytosine arabinoside triphosphate and the duration of remission in patients with acute nonlymphocytic leukemia
166. Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)
167. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Bax/Bcl-2 ratio and loss of spontaneous caspase 3 processing in vivo
168. Shifts in blast cell phenotype and karyotype at relapse of childhood lymphoblastic leukemia
169. Childhood leukemias
170. Acute lymphoblastic leukemia
171. Salvage therapy of refractory, and relapsed acute leukemia with high dose mitoxantrone and high dose cytarabine
172. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT
173. Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation
174. Cytogenetically different leukemic clones at relapse of childhood acute lymphoblastic leukemia
175. Indications for marrow transplantation in acute lymphoblastic leukemia
176. Bcl-2 family proteins: Strategies for overcoming chemoresistance in cancer
177. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
178. A phase II study of high dose ARA-C and mitoxantrone for treatment of relapsed or refractory adult acute lymphoblastic leukemia
179. Refractory acute lymphocytic leukemia: Response to aclacinomycin A and VP-16-213
180. Bone marrow transplantation in first remission
181. Outcomes among 562 recipients of placental-blood transplants from unrelated donors
182. Correlation between leukemic cell retention of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate and response to therapy
183. Doxorubicin and ifosfamide combination chemotherapy in previously treated acute leukemia in adults: A Southwest Oncology Group pilot study
184. Phase II evaluation of teniposide and ifosfamide in refractory adult acute lymphocytic leukemia: A Southwest Oncology Group Study
185. Bcl-2 family members in childhood acute lymphoblastic leukemia: Relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome
186. Autologous bone marrow transplantation
187. Tenoposide and cytarabine combination chemotherapy in the treatment of relapsed adolescent and adult acute lymphoblastic leukemia
188. Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial
189. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion
190. Treatment of acute lymphoblastic leukemia in adults - Results of the L-10 and L-10M protocols
191. Treatment of advanced acute leukaemia with allogeneic bone marrow transplantation from unrelated donors
192. Decitabine (5-Aza-2′-deoxycytidine: DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: Preliminary, observations
193. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: Implications for a continuous infusion schedule
194. Aggressive chemotherapy for acute leukemia relapsed after transplantation
195. Selective inhibition of acute myeloid leukemia using antibody-targeted chemotherapy: A phase I study of an anti-CD33 calicheamicin immunoconjugate
196. Efficacy and safety, of CMA-676 in patients with AML in first relapse
197. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173
198. Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse
199. Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia
200. Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells
201. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia
202. L-Asparaginase-induced modulation of methotrexate polyglutamylation in murine leukemia L5178Y
203. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia
204. Frequent p53 mutation in relapsed acute lymphoblastic leukemia with cytogenetic instability: A longitudinal analysis
205. Therapy of refractory adult acute lymphoblastic leukemia with vincristine and prednisone plus tandem methotrexate and L-asparaginase, Results of a Cancer and Leukemia Group B Study
206. Efficacy of an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against BCR-ABL positive cells
207. Review of 43 patients with adult lymphoblastic leukemia in relapse after initial remission duration over 2 years: Characteristics, response and outcome with salvage therapy
208. Refractory or relapsed Burkitt's type adult lymphoblastic leukemia: Characteristics and outcome with salvage therapy
209. Primary, refractory and relapsed adult acute lymphoblastic leukemia: Characteristics, treatment results, and prognosis with salvage therapy
210. Hyper-CVAD program in Burkitt's type adult acute lymphoblastic leukemia
211. Phase II study of liposomal vincristine (Lipov) in relapsed or refractory adult acute lymphoblastic leukemia (ALL)
212. Nelarabine (GW506U78) and fludarabine (FLU) therapy (Rx) for refractory, leukemias: A pilot study
213. Idarubicin and ifosfamide in the treatment of refractory and relapsed acute lymphoblastic leukemia
214. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia
215. Leukemic cell growth in SCID mice as a predictor of relapse in high-risk B-lineage acute lymphoblastic leukemia
216. Treatment of therapy-refractory B-lineage acute lymphoblastic leukemia with an apoptosis-inducing CD19-directed tyrosine kinase inhibitor
217. Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
218. FLAG (fludarabine, cytarabine, G-CSF) as a second line therapy for acute lymphoblastic leukemia with myeloid antigen expression: In vitro and in vivo effects
219. Proliferation and apoptosis in newly diagnosed and relapsed childhood acute lymphoblastic leukemia
220. Late relapsing childhood lymphoblastic leukemia
221. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh
222. Bax:Bcl-2 ratio modulation by bryostatin 1 and novel antitubulin agents is important for susceptibility, to drug induced apoptosis in the human early pre-B acute lymphoblastic leukemia cell line, Reh
223. Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh
224. Possible roles of an adult T-cell leukemia (ATL)-derived factor/thioredoxin in the drug resistance of ATL to Adriamycin
225. Bcl-2 antisense therapy in patients with non-Hodgkin lymphoma
226. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia: Risk factors and clinical outcome
227. Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia
228. Treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)
229. Impact of reinduction regimens for relapsed and refractory acute lymphoblastic leukemia in adults
230. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients
231. Short-term intensive treatment (VAAP) of adult acute lymphoblastic leukemia and lymphoblastic lymphoma
232. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia: The EORTC Leukemia Cooperative Group
233. Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia
234. Decreased vascular endothelial growth factor expression associated with tumor regression induced by (E)-2′-deoxy-2′-(fluoromethylene) cytidine (MDL 101, 731)
235. Combination chemotherapy for haematological relapse in adult acute lymphoblastic leukemia
236. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia
237. Molecular thanatopsis: A discourse on the BCL2 family and cell death
238. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults
239. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia